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Introduction
Benign breast disease (BBD) is a heterogeneous condition
consisting of many histological entities [1], including ductal
epithelial proliferations, adenomas and papillomas, and fibroadenomas [2]. Some of these lesions are thought to
represent progressive changes in the stepwise sequence of
histological changes leading to the development of breast
cancer. Specifically, it has been hypothesized that non-atypical proliferative forms of BBD, proliferative disease with
atypia, and in situ cancer represent successive steps preceding
the development of invasive breast carcinoma [3]. This
hypothesis is supported by experimental and epidemiologic
evidence. Experimentally, xenografts of MCF10AneoT cells
have been shown to progress from intraductal proliferative
changes to lesions resembling atypical hyperplasia of the
human breast and ultimately to lesions resembling carcinoma
in situ [4]; this step-wise development of breast cancer has
also been demonstrated using transgenic rat [5] and mouse [6]
models. Epidemiologic studies have shown that women with
proliferative epithelial disorders affecting the small ducts and
the terminal ductal lobular units of the breast are at increased
risk of subsequent breast cancer, particularly when the epithelial proliferation is accompanied by evidence of atypia [1,
7–9]. Risk is increased approximately 1.5–2 fold for those
with epithelial proliferation without atypia [7–9] and 4–5 fold
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for those with proliferative disease with atypia [8, 10]. The
higher risk associated with atypia is consistent with the notion
that it is more proximal to carcinoma than proliferative disease
without atypia. Given these findings, benign proliferative
epithelial disorders (BPED) of the breast are considered to
have malignant potential [11]. Our focus in the remainder of
this review is on BPED of the breast.

Descriptive epidemiology
It is difficult to estimate the prevalence and incidence of
benign breast lesions in general, and of BPED of the breast
in particular, since an unknown proportion of women with
BBD come to clinical attention and proceed to biopsy [12].
Nevertheless, autopsy and epidemiological studies have
provided estimates of the frequency of occurrence of BPED.
Several autopsy studies have provided data on the
prevalence of benign proliferative epithelial disorders of
the breast [13–23] at the time of death. The studies differed
somewhat with respect to their use of histopathological
terminology, perhaps accounting for the wide range of
prevalence estimates, which extended from a low of 5–15%
[13, 15] to a high of 64% [22]. The prevalence of BPED
exceeded that of occult carcinoma of the breast substantially in most of these series, suggesting that even if benign
proliferative epithelial disorders of the breast are precursors of breast cancer, they do not necessarily progress to
cancer.
Currently, there are no published estimates of the incidence rate of BPED of the breast. However, incidence rates
of broader groupings of BBD (e.g., fibrocystic disease or
benign mammary dysplasia) have been shown with considerable consistency to increase rapidly with age until
about 40–44 years, with peak incidence rates being
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OR = 0.8 (0.2–2.5)

OR = 1.35 (0.86–2.10)

‡17 vs. £13

[13 vs. £13
382 (165)
OR = odds ratio
RR = relative risk,

b

Nested case–control
Friedenreich et al. [54]

a

1,130 (33)
Case–control
Wu et al. [53]

Proliferative benign breast disease

Case–control
Minami et al. [41]

Fibrocystic disease with atypia

Canada

OR = 0.78 (0.39–1.53)
‡16 vs. £13
260 (130)

Case–control
London et al. [40]

Proliferative benign breast disease

China

OR = 0.7 (0.4 – 1.2)

Japan

b

14+ vs. £12

Case–control
Ingram et al. [39]

Proliferative benign breast
disease without atypia
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United States

No difference
Comparison of mean age
(cases vs. controls)
Western Australia
300 (91)

RR = 1.3 (0.9–1.9)

RR = 0.69 (0.36–1.3)
\13 vs. ‡13
306 (172)
Case–control
Bright et al. [35]

Benign breast disease, all cases

Case–control
Parazzini et al. [31]

Benign epithelial hyperplasia

a

United States

No difference

\14 vs. ‡14

Finland

Italy
488 (203)

844 (422)
Case–control
Soini [2]

Dysplasia (ductal, other, mixed)

Population
(source)
Number of
study participants
(No. cases)
Case definition
Study design

Studies of hormonal and reproductive factors have focused
on aspects of these exposures that have also been studied in
relation to breast cancer, including age at menarche, parity,
age at first birth, and use of exogenous hormones. The
association between age at menarche and BPED of the breast
has been investigated in nine case–control studies [2, 31, 33–
35, 39–41, 53] and one cohort study [54], none of which has
shown alterations in risk (Table 1). Of the studies that
examined age at first birth [2, 30, 31, 33, 34, 40–42, 53, 54],
two found statistically significant positive associations with
older ages at first birth [30, 34] and one reported a 3-fold

Reference

Hormonal and reproductive factors

Table 1 Association between age at menarche (years) and risk of BPED of the breast

There have now been several case–control [2, 30–53] and
cohort studies [54–61] of the etiology of benign proliferative epithelial disorders of the breast. These studies have
reported either on the risk of such lesions overall [2, 30–
32, 34–41, 47–52, 54–57, 59, 62] or on risk by the degree
of epithelial proliferation or cytological atypia displayed in
the benign lesions [33, 34, 36, 37, 42–46], and they have
generally focused on factors that have been studied in
relation to the etiology of breast cancer. The rationale for
this is that if BPED of the breast are indeed precursors of
breast cancer, then BPED and breast cancer would be
expected to have similar risk factors. At the very least, risk
factors for the former would be expected to be a subset of
those for the latter (since factors other than those responsible for the development of BPED might be responsible
for the progression of BPED to breast cancer). In relation
to the etiology of breast cancer, there is evidence to support an increased risk of breast cancer in association with a
number of hormonal and reproductive factors including
nulliparity, a relatively late age at first pregnancy, a relatively late age at natural menopause, and use of hormone
replacement therapy [63]. In addition, there is evidence to
support a positive association between ionizing radiation
exposure, family history of breast cancer, alcohol consumption, and obesity in postmenopausal women [63]. In
contrast, there is some evidence of an inverse association
between physical activity, breast-feeding, and fruit and
vegetable consumption and breast cancer risk [64, 65].

Comparison

Etiology

Ductal epithelial hyperplasia

Risk estimate
(95% CI)

somewhere between 200 and 400/100,000/year, after
which they decline rapidly [2, 24–28]. The disease remains
relatively common after the menopause, with estimates of
the annual incidence rate ranging from about 100/100,000
women in the early postmenopausal years to 20–30/
100,000 women in the later postmenopausal years [29].

Mean age at menarche
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Outcome: mean ductal atypia score 2.30–3.00
c

Outcome: mean ductal atypia score 2.375–3.000,
b

OR = odds ratio,

Case–control
Case–control
Nested case–control
Minami et al. [41]
Wu et al. [53]
Friedenreich et al. [54]

a

OR = 3.27 (1.37–7.78)
OR = 0.3 (0.1–1.2)
OR = 1.27 (0.62 – 2.60)
Nulliparous vs. £24
‡32 vs. £24
‡26 vs. nulliparous
260 (130)
1,130 (33)
382 (165)

Japan
China
Canada

OR = 1.0 (0.5–1.9)
United States
576 (173)

Proliferative benign breast
disease without atypia
Proliferative benign breast disease
Fibrocystic disease with atypia
Proliferative benign breast disease
Case–control
London et al. [40]

No difference

a

No difference
OR = 12 (2.43–59.30)
OR = 1.8
OR = 0.85 (0.90–1.53)
No difference

Mean age at first birth
‡25 vs. \25
‡30 vs. \20
Continuous (increase of 1 year)
Mean age at first birth
(premenopausal women)
vs. controls
Mean age at first birth
(premenopausal
women) vs. controls
29+ vs. \21
Finland
United States
Italy
United States
United States
844 (422)
66 (33)
570 (285)
1,146 (218)
1,608 (590)
Ductal epithelial hyperplasia
Proliferative benign breast disease
Dysplasia (ductal, other, mixed)
Fibrocystic disease with high atypiab
Papillary hyperplasia with high atypiac

Comparison
Population
(source)
Number of study
participants
(No. cases)
Case definition

Case–control
Case–control
Case–control
Case–control
Case–control

Several studies have examined weight and/or body mass
index as risk factors. Of these studies, four have yielded
findings suggesting an inverse association with either body
weight [34, 39] or body mass index [31, 38] and five others
have found no association [2, 33, 35, 40, 54] (Table 7).
Only three of these studies, however, has examined this
association by menopausal status [35, 40, 54]. Bright et al.
[35], found a non-significant inverse association between
obesity and BPED in both premenopausal (OR = 0.75,

Soini [2]
Lance [30]
Parazzini et al. [31]
Hsieh et al. [42]
Berkowitz et al. [33]

Anthropometric and lifestyle factors

Study design

The literature regarding the association between family
history of breast cancer and risk of BPED is mixed, with
some studies finding a positive association BPED [34, 41]
and others [33, 35, 39, 40, 53, 54] observing no association
(Table 6).

Reference

Family history

Table 2 Association between age at first birth/pregnancy and risk of BPED of the breast

increase in risk among nulliparous women compared to
women whose age at first birth was £24 years [41] (Table 2);
the remaining seven studies found no association [2, 31, 33,
40, 42, 53, 54]. In relation to parity, only three [35, 41, 53] of
11 studies [2, 31, 33–35, 39–42, 53, 54] have supported an
inverse association with risk, while the remaining studies
observed no association (Table 3). There appears to be no
association between either abortion [2, 34] or breast feeding
history and risk [2, 41, 53, 54].
Several studies have also examined the etiological role
of exogenous hormone use [35, 43–47, 54, 56]. Four
studies, two cohort [54, 56] and two case–control [35, 43],
have presented results for the association between oral
contraceptive (OC) use and risk of BPED (Table 4), with
two showing that risk of BPED was reduced in association
with OC use [35, 56] and the others [43, 54] showing no
association. Several other studies (all case–control) have
reported on the association between OC use and risk of
BBD by degree of histological atypia [42–46]. Findings for
these studies have varied from those showing reduced risk
of all grades of atypia [42] to those showing no reduction in
risk with any grade of atypia [43]. With respect to hormone
replacement therapy (HRT), while the cohort study by
Rohan and Miller [47] observed a statistically significant
increased risk of BPED in association with use of more than
8 years, earlier case–control studies, in which the association between HRT use and risk of BBD was examined by
degree of histological atypia, found no evidence for a
relationship [35, 46] (Table 5). In addition, a recent cohort
study conducted by Friedenreich et al. [54] observed no
association between HRT use and risk of BPED.

Risk estimate (95% CI)
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Case–control

Case–control

Case–control

Case–control

Case–control

Case–control

Case–control

Case–control

Nested case–control

Parazzini et al. [31]

Hsieh et al. [42]

Berkowitz et al. [33]

Bright et al. [35]

Ingram et al. [39]

London et al. [40]

Minami et al. [41]

Wu et al. [53]

Friedenreich et al. [54]

Proliferative benign breast disease

Fibrocystic disease with atypia

Proliferative benign breast disease

Proliferative benign breast
disease without atypia

Proliferative benign breast
disease

Proliferative benign breast
disease without atypia

Papillary hyperplasia with
high atypiae

Fibrocystic disease with high atypia

Dysplasia (ductal, other, mixed)

Ductal epithelial hyperplasia

Case
definition

382 (165)

1,130 (33)

260 (130)

576 (173)

300 (99)

306 (172)

1,608 (590)

1,146 (218)

570 (285)

844 (422)

Number of study
participants
(No. cases)

Canada

China

Japan

United States

Western Australia

United States

United States

United States

Italy

Finland

Population
(source)

OR = 1.24 (0.62–2.51)
OR = 1.44 (0.71–2.93)

OR = 0.1 (0.02–0.6)

‡3 vs. nulliparous
‡4 vs. nulliparous

OR = 0.29 (0.12–0.69)

‡3 vs. nulliparous
Parous vs. nulliparous

OR = 1.0 (0.5–1.9)

No difference

RR = (0.29 (0.12–0.71)

b

3+ vs. nulliparous

Comparison of mean parity
(cases vs. controls)

Parous vs. nulliparous

No difference

Mean number of live births
vs. controls (postmenopausal
women)

OR = 1.06 (0.39–2.90)

Parity 5+ vs. 1-2d

No difference

OR = 2.2
OR = 0.82 (0.18–3.71)

Parity 3–4 vs. 1–2c
Mean number of live births
vs. controls (premenopausal
women)

No difference
a

Mean number of births

Risk estimate (95% CI)

‡3 vs. nulliparous

Comparison

OR = odds ratio, b RR = relative risk, c Outcome: mean ductal atypia score 2.375–3.000,d Outcome: mean ductal atypia score 1.875–2.250, e Outcome: mean ductal atypia score 2.30–3.00

Case–control

Soini [2]

a

Study
design

Reference

Table 3 Association between parity and risk of BPED of the breast
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Case–control

Case-cohort

Case–control
Case–control

Case–control
Case–control
Nested case–control
Case–control

Rohan et al. [43]

Rohan and Miller [56]

Li Volsi et al. [44]
Pastides et al. [45]

Berkowitz et al. [32]
Wu et al. [53]
Friedenreich et al. [54]
Bright et al. [35]

Outcome: mean ductal atypia score 2.00–2.74,

c

Outcome: mean ductal atypia score 2.30–2.75, OR = odds ratio

b

c

306 (172)

6,134 (691)

382 (165)

IRR = incidence rate ratio,

Case–control Proliferative benign breast disease

Bright et al. [35]

a

Case–control Proliferative benign breast disease

Rohan and Miller [47]

Friedenreich et al. [54] Case–control Proliferative benign breast disease

Case–control Fibrocystic disease with high atypiaa 1,608 (590)

Berkowitz et al. [46]

d

d

RR = relative risk

United States

NBSS

Canada

United States

OR = 8.8 (1.8–41.8)
OR = 0.6 (0.01–4.8)
OR = 0.98 (0.64–1.51)
f
RR = 0.35 (0.16–0.76)

OR = 0.9 (0.5–1.5)
OR = 0.9 (0.4–1.9)
OR = 0.9 (0.4–1.7)
e
IRR = 0.92 (0.77–1.10)
IRR = 0.68 (0.51–0.90)
IRR = 1.04 (0.80–1.35)
OR = 3.00 (Ptrend = 0.2)
OR = 0.7 (ns)
No difference

d

Risk estimate (95% CI)

OR = 0.9 (0.2–5.1)

b

OR = 1.29 (0.80–2.11)

[4 vs. 0 years

RR = 0.69 (0.36–1.3)

d

‡97 vs. 0 months
Ever vs. never

IRR = 1.45 (1.00–2.11)
IRR = 1.70 (1.06–2.72)

Current vs. never

c

OR = 1.18 (0.77–1.81)

Ever vs. never

‡5 years vs. never OR = 3.0 (0.5–17.5)

Ever vs. never

Risk estimate (95% CI)

OR = odds ratio, e IRR = incidence rate

Ever vs. never
‡96 months vs. never
‡30 vs. \20 years old at first use
Ever vs. never
‡85 months vs. never
‡16 years since last use vs. never
Ever vs. never
Ever vs. never
Mean duration of use in months
(SE) for cases vs. controls
Ever vs. never
[1 year vs. never
Ever vs. never
Ever vs. never

Comparison

Number of study participants (No. cases) Population (source) Comparison

Study design Case definition

Reference

United States
China
Canada
United States

United States
United States

NBSS

South Australia

Population
(source)

Outcome: mean ductal atypia score 1.8–2.29,

1,608 (590)
1,130 (33)
382 (165)
306 (172)

Fibrocystic disease with high atypiac
Fibrocystic disease with atypia
Proliferative benign breast disease
Proliferative benign breast disease
b

410 (205)
1,045 (255)

7,454 (2,116)

575 (383)

Number of study
participants
(No. cases)

Fibrocystic disease with high atypiaa
Fibrocystic disease with high atypiab

Proliferative benign breast disease

Proliferative benign breast disease

Case definition

Table 5 Association between use of hormone replacement therapy and risk of BPED of the breast

Outcome: mean ductal atypia score 2.3–2.75,
ratio, f RR = relative risk

a

Study design

Reference

Table 4 Association between oral contraceptive use and risk of BPED of the breast
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123

123

OR = 1.30 (0.24–1.48)
Yes vs. noc
Canada
a

b

c

RR = relative risk, OR = odds ratio, Maternal history of breast cancer

382 (165)
Nested case–control
Friedenreich et al. [54]

Proliferative benign breast disease

OR = 4.13 (1.46–11.71)

OR = 3.2 (0.04–63.2)
First degree family
history yes vs. no

Yes vs. no
Japan

China
1,130 (33)

260 (130)
Proliferative benign breast disease

Wu et al. [53]

Fibrocystic disease with atypia

Case–control

Case–control

Minami et al. [41]

OR = 0.9 (0.5–1.6)

Yes vs. no
United States
576 (173)
Case–control
London et al. [40]

Proliferative benign breast disease
without atypia

RR = 1.1 (0.54–2.4)
United States
306 (172)
Case–control
Bright et al. [35]

Benign breast disease, all cases

b

a

No difference

Comparison of % first
degree family history
(cases vs. controls)
Yes vs. no
Western Australia
300 (99)
Case–control
Ingram et al. [39]

Benign epithelial hyperplasia

Number of study
participants (No. cases)
Case
definition
Study
design
Reference

Table 6 Association between family history of breast cancer and risk of BPED of the breast

Population
(source)

Comparison

Risk
estimate (95% CI)
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95% CI = 0.38–1.5) and postmenopausal women (OR =
0.86, 95% CI = 0.40–1.8). In contrast, Friedenreich et al.
[54], in a study population including 93% postmenopausal
women, reported a non-significant 12% increased risk for
women with a BMI ‡29.5 vs. \22.9 (95% CI = 0.63–
1.97). Similarly, London et al. [40] found that, among
postmenopausal women, there was a 30% increased risk of
BPED for those who weighted [165 lbs compared to
women who weighed \124 lbs. Given that BMI is positively associated with breast cancer risk among
postmenopausal women, and there is some evidence that
BMI may be inversely associated with risk in premenopausal women [66–68], it is possible that the conflicting
data are due to the lack of stratification by menopausal
status in the majority of these studies. To date, only two
studies have examined the role of physical activity; in each
of these studies there was no association with risk [52, 54].
Several studies have also examined lifestyle factors
such as diet, alcohol consumption and cigarette smoking
[32, 33, 36, 37, 39, 40, 48–50, 53–55, 57, 58, 60–62]. Of
these studies, none of those which examined smoking
history showed an association with risk [32, 33, 37, 54, 57,
61] (Table 8). Four studies have examined the association
between alcohol consumption and risk. Of these, one [58]
observed significant inverse associations between total
alcohol intake and intake of wine and spirits, separately,
and risk, while an earlier study [36] found no association
(Table 9). More recently, a cohort studies by Friedenreich
et al. [54] and Cui et al. [60] likewise observed no association between alcohol consumption and risk.
Aspects of diet have also been investigated in several
studies as potential risk factors for BPED [38, 39, 47, 49,
50, 55, 59, 60, 62] (Table 10). While none of the studies to
date support an association with total energy intake [48,
53, 55, 59], some studies have shown positive associations
between saturated fat intake (or indices thereof) and risk of
atypical [51] or proliferative forms [62] of BBD, although
others [39, 48, 49, 55, 59] have provided little support for
associations with dietary fat.
In relation to dietary fiber, Baghurst and Rohan [50]
found strong inverse associations with total dietary fiber
and its constituents (soluble and insoluble non-starch
polysaccharides and cellulose). While these findings were
supported to some extent by those of another study [39] in
which risk of benign epithelial hyperplasia was reduced in
association with consumption of fruit and leafy orange-red
vegetables, others have observed no association between
dietary fiber and risk [48, 55, 59]. Although Rohan et al.
[48] provided some evidence for inverse associations
between b-carotene intake and risk, a study by London
et al. [40] showed that neither b-carotene nor retinol intake
was associated with altered risk of atypical or non-atypical
forms of BPED. Webb et al. [59] found no association

Case–control

Case–control

Case–control

Case–control

Case–control

London et al. [40]

Parazzini et al. [31]

Soini et al. [2]

Berkowitz et al. [33]

Pastides et al. [34]

c

Nested
case–control

Friedenreich et al. [54]

RR = relative risk,

Case–control

Ingram et al. [39]

b

Case–control

Bright et al. [35]

OR = odds ratio,

Case–control

Ingram et al. [38]

a

Study
design

Reference

premenopausal,

d

postmenopausal,

Fibrocystic breast disease

Fibrocystic breast disease

Ductal epithelial hyperplasia

Dysplasia (ductal, other, mixed)

Proliferative benign
breast disease
without atypia

Proliferative
benign breast disease

Benign epithelial hyperplasia

Benign breast disease, all cases

Benign epithelial hyperplasia

Case
definition

e

United States

United States

Finland

Italy

United States

Canada

Western Australia

United States

Western Australia

Population
(source)
a

[26 vs. £20

OR = 0.8 (0.7–0.9)
OR = 1.0

10 lb increase in weight
women ‡55 years of age

OR = 0.4 (0.3–0.7)

£25 vs. £20
10 lb increase in weight
women \55 years of age

No difference
No difference

OR = 0.9

‡25 vs. £20
Mean height

OR = 1.3 (0.7–2.6)

165+ vs. £124 lbd

Mean weight

OR = 1.12 (0.63–1.97)
OR = 0.83 (0.46–1.50)

Weight gain since
18 ‡26.2 vs. \6.8 kge

62.1 vs. 64.2 kg (P \ 0.05)

Comparison of mean
weight
(cases vs. controls)
‡29.5 vs. \22.9

23.45 vs. 25.46 (P \ 0.05)

Comparison of mean
BMI (cases vs. controls)

RR = 0.86 (0.40–1.8)

RR = 0.75 (0.38–1.5)
b

Obese vs. non-obesed

Obese vs. non-obese

b

c

OR = 0.27 (0.09–0.86)

Risk estimate
(95% CI)

Comparison

approximately 93% of study subjects were postmenopausal

1,015 (225)

1,608 (590)

844 (422)

570 (285)

576 (173)

382 (165)

300 (99)

118 (47)

188 (125)

307 (96)

Number of study
participants
(No. cases)

Table 7 Association between body mass index/weight/height and risk of BPED of the breast
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123

123

Prospective cohort

Cui [61]

IRR = incidence rate ratio,

Proliferative benign
breast disease

Proliferative benign
breast disease

Dysplasia (ductal,
other, mixed)

Proliferative benign
breast disease

Proliferative benign
breast disease

Case
definition

d

Study design

Case definition

b

RR = relative risk,

c

Prospective cohort

Cui et al. [60]

OR = odds ratio,

Case–control

Rohan et al. [36]

a

Case-cohort

Rohan et al. [58]

958 (383)

5,585 (557)

382 (165)

HR = hazard ratio

Proliferative benign breast disease 68,132 (1,792)

Proliferative benign breast disease

Proliferative benign breast disease

Friedenreich et al. [54] Nested case–control Proliferative benign breast disease

Reference

Women’s health initiative

NBSS

Italy

South Australia,
postmenopausal

Canada

Population
(source)

OR = 0.76 (0.35–1.65)
OR = 0.41 (0.26–0.66)

‡10 vs. 0 g/day (beer)
‡10 vs. 0 g/day (wine)

RR = 0.6 (0.3–1.3)
RR = 0.7 (0.4–1.1)

‡10 vs. 0 g/day (wine)

HR = 1.02 (0.84–1.24)
HR = 0.89 (0.63–1.26)

c

‡10 vs. 0 g/day (spirits) RR = 0.9 (0.4–2.2)

OR = 1.0 (0.6–1.7)
b

[10 vs. 0 g/day (total)
‡10 vs. 0 g/day (beer)

‡10 vs. 0 g/day (spirits) OR = 0.46 (0.31–0.71)

OR = 0.23 (0.13–0.40)

‡30 vs. 0 g/day (total)

OR = 1.15 (0.74–1.78)
OR = 1.15 (0.69–1.91)

a

Risk estimate (95% CI)

RR = 1.3 (0.5–3.1)
OR = 1.2 (0.8–1.8)
OR = 0.7 (0.4–1.3)
OR = 1.0 (0.6–1.6)
OR = 1.4 (0.7–2.8)
c
IRR = 0.81 (0.64–1.03)
IRR = 1.17 (0.97–1.41)
IRR = 0.92 (0.69–1.23)
d
HR = 0.97 (0.88–1.08)
HR = 1.00 (0.90–1.11)
HR = 0.84 (0.69–1.02)

OR = 0.87 (0.57–1.31)
OR = 0.75 (0.26–2.19)
b
RR = 0.9 (0.6–1.2)
RR = 1.7 (0.7–4.2)

a

Risk estimate
(95% CI)

‡224 vs. 0

Any vs. none

Comparison

Ever vs. never smoker
‡15 vs. 0 pack years
Ever vs. never
Cigarette years ‡300
vs. never
Ever vs. never
Current vs. never
Former vs. never
‡10 vs. 0 cigarettes/day
‡20 vs. 0 years smoking
Current vs. never
Ex-smoker vs. never
Cigarette years [550 vs never
Ever vs. never
Ex-smoker vs. never
Current vs. never

Comparison

Women’s health initiative Former vs. never
30 g/day vs. never

Australia

NBSS

Canada

Number of study
Population
participants (No. cases) (source)

HR = hazard ratio

68,132 (1,792)

6,134 (691)

579 (288)

575 (382)

382 (165)

Number of study
participants (No. cases)

Table 9 Association between alcohol consumption and risk of BPED of the breast

c

Case-cohort

Rohan [57]

RR = relative risk,

Case–control

Parazzini et al. [32]

b

Case–control

Rohan et al. [37]

OR = odds ratio,

Nested case–control

Friedenreich et al. [54]

a

Study
design

Reference

Table 8 Association between smoking history and risk of BPED of the breast
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Case-cohort
Case–control
Case–control
Prospective cohort

Case–control

Case–control

Case–control
Case–control
Case–control

Case-cohort
Prospective cohort

Case–control

Case-cohort
Case–control
Case–control
Prospective Cohort

Case–control

Fat
Lubin et al. [51]

Hislop et al. [62]

Rohan et al. [48]
Ingram et al. [39]
London et al. [49]

Rohan et al. [55]
Webb et al. [59]

Dietary fiber
Baghurst and Rohan [50]

Rohan et al. [55]
Rohan et al. [48]
Ingram et al. [39]
Webb et al. [59]

Fruits & vegetables
Ingram et al. [39]

Study
design

Energy
Rohan et al. [55]
Rohan et al. [48]
Wu et al. [53]
Webb et al. [59]

Reference

Benign epithelial hyperplasia

Proliferative benign breast disease
Proliferative benign breast disease
Benign epithelial hyperplasia
Proliferative benign breast
disease without atypia

Proliferative benign breast disease

Proliferative benign breast disease
Benign epithelial hyperplasia
Proliferative benign breast disease
without atypia
Proliferative benign breast disease
Proliferative benign breast disease
without atypia

Proliferative benign breast disease

Atypical benign breast
disease grade 3+

Proliferative benign breast disease
Proliferative benign breast disease
Fibrocystic disease with atypia
Proliferative benign breast disease
without atypia

Case
definition

Table 10 Association between dietary factors and risk of BPED of the breast

(545)
(383)
(33)
(786)

(545)
(383)
(99)
(786)

300 (99)

5,466
575
300
58,628

708 (354)

5,466 (545)
58,628 (786)

575 (383)
300 (99)
573 (176)

248 (124)

2,332 (854)

5466
575
1,130
58,628

Number of study
participants (No. cases)

Western Australia

Canada
South Australia
Western Australia
United States

South Australia

Canada
United States

South Australia
Western Australia
United States

Canada

Israel

Canada
South Australia
China
United States

Population
(source)

Median consumption (fruit)
Median consumption
(vegetables)

Q5 vs. Q1 (community
controls)
Q5 vs. Q1 (biopsy negative
controls)
Q5 vs. Q1
Q5 vs. Q1
Median consumption
‡21.1 vs. £14.7 g

Q5 vs. Q1
‡70 vs. £55.7 g

Q4 vs. Q1 saturated fat
(surgical controls)
Q4 vs. Q1 saturated fat
(neighborhood controls)
Frequent vs. rare intake (meat
fat)
Frequent vs. rare intake
(dairy fat)
Q5 vs. Q1 (total fat)
Median consumption
Q5 vs. Q1 (total fat)

Q5 vs. Q1
Q5 vs. Q1
[2,128 vs. \1,647.3 kcal
‡2,128 vs. £1,390 kcal

Comparison

IRR = 0.90 (0.67–1.22)
OR = 1.6 (0.9–3.0)
OR = 0.7 (0.2–1.9)
c
RR = 0.93 (0.76–1.14)

OR = 0.8 (0.4–1.5)
OR = 1.2 (0.7–2.1)

IRR = 1.11 (0.82–1.50)
OR = 1.4 (0.8–2.9)
OR = 0.8 (0.5–1.5)
RR = 0.99 (0.81–1.21)

OR = 0.45 (0.24–0.82)

OR = 0.64 (0.34–1.19)

IRR = 0.88 (0.65–1.20)
RR = 1.01 (0.83–1.23)

OR = 2.1 (1.2–3.8)
OR = 0.8 (0.5–1.6)
OR = 1.2 (0.6–2.6)

OR = 0.72 (0.34–1.53)

OR = 1.49 (0.66–3.36)

OR = 3.8 (1.3–10.7)

OR = 3.6 (1.4–9.4)

b

a

Risk estimate
(95% CI)
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Prospective cohort

Case-cohort

Cui et al. [60]

Calcium
Rohan et al. [55]

IRR = incidence rate ratio,

Prospective cohort

Webb et al. [59]

b

Case–control

Ingram et al. [39]

a

Case–control

London et al. [40]

OR = odds ratio,

c

RR = relative risk,

d

5,466 (545)

68,132 (1,792)

58,628 (786)

300 (99)

576 (173)

5,466 (545)

575 (383)

Number of study
participants (No. cases)

HR = hazard ratio

Proliferative benign breast disease

Proliferative benign breast disease

Proliferative benign breast disease
without atypia

Benign epithelial hyperplasia

Proliferative benign breast disease
without atypia

Proliferative benign breast disease

Case-cohort

Rohan et al. [55]

Case
definition

Proliferative benign breast disease

Study
design

Retinol/b-carotene/vitamin E/folate
Rohan et al. [48]
Case–control

Reference

Table 10 continued

NBSS

Women’s health initiative

United States

Western Australia

United States

NBSS

South Australia

Population
(source)

Q5 vs. Q1

Q5 vs. Q1 (retinol)
Q5 vs. Q1 (b-carotene)
Q5 vs. Q1 (retinol)
Q5 vs. Q1 (b-carotene)
Q5 vs. Q1 (retinol)
Q5 vs. Q1 (carotene)
Q5 vs. Q1 (Vitamin E)
Median consumption (retinol)
Median consumption (bcarotene)
‡2,525 vs. £1,130 equivalents
of vitamin A lg (retinol)
[16.2 vs \7.7 mg (vitamin
E)
[748 vs. \351 lg/day
(folate-all sources)
[430 vs. \320 lg/day
(folate-diet)
Supplement use yes vs. no

Comparison

=
=
=
=
=
=
=
=
=

1.1 (0.6–2.0)
0.8 (0.4–1.4)
0.97 (0.71–1.31)
0.94 (0.70–1.27)
0.8 (0.4–1.7)
1.5 (0.7–3.5)
1.5 (0.7–3.4)
1.2 (0.6–2.1)
0.9 (0.5–1.7)

HR = 1.04 (0.91–1.20)

IRR = 0.81 (0.60–1.07)

HR = 1.00 (0.91–1.11)

HR = 1.09 (0.95–1.25)

d

RR = 0.84 (0.65–1.09)

RR = 1.07 (0.85–1.34)

OR
OR
OR
OR
OR
OR
OR
OR
OR

Risk estimate
(95% CI)
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between either carotene or vitamin A consumption and risk
of proliferative BBD without atypia or of atypical hyperplasia. Recently, Cui et al. [60] found no association
between dietary or supplemental folate and risk of either
non-atypical BPED or atypical hyperplasia.
Conclusion
Epidemiologic studies have shown that women with benign
proliferative epithelial disorders of the breast are at increased
risk of subsequent breast cancer [1, 7, 8], and it has been
hypothesized that BPED of the breast may be pre-malignant
lesions [29]. To date, studies of the etiology of BPED of the
breast have revealed both differences and similarities to that
of breast cancer. For example, although younger age at
menarche has been shown to be associated with an increased
risk of breast cancer [63], none of the studies that have
examined age at menarche in relation to risk of BPED have
found an association. Similarly, there does not appear to be
any association between age at first birth/pregnancy and
BPED risk, while this is an established risk factor for breast
cancer [63]. In addition, most studies have observed no
association between oral contraceptive use [43–45, 54] and
risk of BPED, while OC use is a probable risk factor for
breast cancer [63]. In contrast, there is some evidence of that
both BPED and breast cancer are positively associated with
hormone replacement therapy [46, 47, 63] and inversely
associated with parity [35, 41, 63]. Discrepancies between
reported risk factors for BPED and those for breast cancer are
not surprising, given the selection bias and misclassification
of outcome to which studies of the former are prone [1]. This
limitation suggests that further advances in elucidating the
epidemiology of BPED of the breast may come from prospective studies conducted in screened populations and using
standard schemes for the classification of BPED. However,
given the methodologic challenges, epidemiologic approaches seem unlikely to be able to confirm that BPED of the
breast are breast cancer precursors. In contrast, molecular
studies may shed further light on the BPED-breast cancer
relationship if they can demonstrate that human breast cancers arise from clonal outgrowths of pre-existing benign
lesions, such as BPED. Nevertheless, even in the absence of
such information, the currently available evidence suggests
that women with BPED of the breast warrant regular surveillance given the increase in subsequent breast cancer risk
that they experience.
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